Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - Generic Drugs - March 24, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/15 - Correction: Financial Markets-The Year in Deals story
NEW YORK In a story Dec. 30 about global deals, The Associated Press reported erroneously that Dow DuPont's products will include Ziploc bags and Saran Wrap. Dow Chemical developed those products but sold them to S.C. Johnson & Son.
12/31/15 - EISAI COMPLETES ACQUISITION OF CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL
Release date- 28122015- Eisai Co., Ltd. announced today that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical Co., Ltd. previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in Chi
12/31/15 - Japan : EISAI completes Acquisition of Chinese Generic Pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. [TendersInfo (India)]
Eisai Co., Ltd. announced today that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical Co., Ltd. previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in China, and the acquisition
12/31/15 - Teligent, Inc. Announces Fourteenth & Fifteenth ANDA Submissions Of 2015
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
12/31/15 - TORRENT GETS US NOD FOR ARTHRITIS DRUG
Torrent Pharmaceutical Ltd has obtained the approval of the US Food and Drug Administration to launch a generic arthritis drug. The company will launch Celacoxib capsules in 50 mg, 100 mg, 200 mg and 400 mg strengths. The drug is the generic version of Celebrex capsules of Pfizer.
12/31/14 - American Consumer Institute's Capitol Hill Event Showcases Benefits of Biosimilars Competition for Patients and Taxpayers [Manufacturing Close - Up]
The FDA has not yet created a pathway for biosimilar drugs to enter the U.S. market, even though other countries have approved these lifesaving drugs as far back as 2006. ". Leigh Purvis, Director of AARP's Health Services Research, spoke of how consumers will benefit from biosimilars competition. The median income among Medicare beneficiaries is a
12/31/14 - Bioequivalence and Biopharmaceutical Committee inaugurated [Ghana News Agency]
Accra, Dec 31, GNA- The Ministry of Health on Tuesday inaugurated a Bioequivalence and Biopharmaceutical Research Centre Steering Committee to support local production of generic medicines for critical public health concerns including Tuberculosis, Malaria and HIV/AIDS. Dr Kwaku Agyeman-Mensah, Minister of Health, inaugurating the committee, said t
12/31/14 - Biosimilars - Biosimilars on the Cusp of a New Era
In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies- the FDA and EMA. Moreover, there are some concerns around biosimilar use, for example w
12/31/14 - Fitch Affirms Teva's Ratings at 'BBB+'; Outlook Stable [Professional Services Close - Up]
Teva is the world's largest generic drug manufacturer and a top-20 global pharmaceutical company. The risk remains that Teva's top-selling drug, Copaxone, could face generic competition in the U.S. at any time and by May 2015 in most of Europe. However, this risk has been mitigated by Teva's successful conversion of nearly two-thirds of U.S. pa
12/31/14 - LUPIN GETS US FDA APPROVAL FOR HIV DRUG
The pharmaceutical company Lupin Ltd has received provisional approval from the United States Food and Drug Administration to market its generic version of Prezista tablets indicated for the. The company can market its Darunavir Ethanolate tablets in multiple strengths in the US market for treatment of HIV-1 infections. The sales data for Sep 2014
12/31/14 - United States : TPI in talks with well capitalised strategic partner [TendersInfo (India)]
A pharmaceutical firm that specialises in patented biopharmaceutical, modernised traditional Chinese medicine, branded generics and active pharmaceutical ingredients, Tianyin Pharmaceutical Co, announced that the firm is engaged in discussion with a pharmaceutical industry strategic partner to form an Alliance in building a nationwide mTCM...
12/31/13 - IGI Laboratories Completes Sixth ANDA Filing for 2013 Under Joint Drug Development And Commercialization Agreement
IGI Laboratories today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. The agreement designates IGI Laboratories, Inc. as the developer and manufacturer of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United Sta
12/31/13 - IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. The agreement designates IGI Laboratories, Inc. as the developer and manufacturer of a generic topical pharmaceutical drug product,.
12/31/13 - Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
The major players include Hospira, Sandoz, Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is likely to remain elusive to all but a select few. Among these, as the only US-based company with approval for biosimilars i
12/30/15 - Bharat Book Bureau: Biosimilars: Global Markets
The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate of 15% from 2014 through 2019.. -Detailed analysis of the emerging regulatory framework in regulated markets as well as comparisons of biosimilar guidelines
12/30/15 - Dr. Reddy's Announces the Relaunch of Esomeprazole Magnesium Delayed-Release Capsules, USP
Reddy s today announced the re-launch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium Delayed-Release capsules in the US market. Nexium is a registered trademark of ASTRAZENECA AB CORPORATION. Reddy s Laboratories Ltd. is an integrated pharmaceutical company, committed to accele
12/30/15 - Guardian sees growth boost [New Straits Time (Malaysia)]
KUALA LUMPUR: THE implementation of the Trans Pacific Partnership pact should pave the way for positive growth for the pharmaceutical industry in Malaysia, said Guardian Malaysia chief executive officer Peter J. Dove. "I will be disappointed if the TPP meant that we could not bring down the prices of generic drugs, as one of the things we are look
12/30/15 - How to spend $5 trillion: a record-breaking year in deals
The highest price tag came in November, when Pfizer and Allergan announced the biggest pharmaceutical deal in history. Pfizer, the maker of cholesterol fighter Lipitor, impotence treatment Viagra and fibromyalgia drug Lyrica, agreed to buy Allergan in November. It would give Pfizer control of Botox and move the company's headquarters to Ireland, cu
12/30/15 - Japan : Takeda Announces Details of New Business Venture with Teva in Japan [TendersInfo (India)]
Takeda Pharmaceutical Company Limited today announced the details of the business venture which was disclosed November 30, 2015 in the press release titled, "Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan". Takeda will split off its off-patented and da
12/30/15 - Teligent, Inc. Added To NASDAQ Biotechnology Index NBI
By a News Reporter-Staff News Editor at Biotech Week Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced that it has been selected for addition to the NASDAQ Biotechnology Index . The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as ei
12/30/15 - The biggest acquisitions planned in 2015, when companies agreed to $5 trillion in deals
NEW YORK Companies around the world spent a record $5.03 trillion on acquisitions in 2015, according to Dealogic, as slow worldwide economic growth and low interest rates pushed companies to combine forces.
12/30/15 - The record-breaking year in deals
The highest price tag came in November, when Pfizer and Allergan announced the biggest pharmaceutical deal in history. Pfizer, the maker of cholesterol fighter Lipitor, impotence treatment Viagra and fibromyalgia drug Lyrica, agreed to buy Allergan in November. It would give Pfizer control of Botox and move the company's headquarters to Ireland, cu
12/30/14 - Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject Injection
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject? Injection, a proprietary nonsteroidal anti-inflammatory drug analgesic. As a result, various medical organizations are now recommending a mult
12/30/14 - Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject?(diclofenac sodium) Injection
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject? Injection, a proprietary nonsteroidal anti-inflammatory drug analgesic. As a result, various medical organizations are now recommending a mu
12/30/14 - OncoGenex Pharma To Regain Rights To Custirsen From Teva Pharmaceutical
This transfer of rights would occur in connection with the termination of the collaboration agreement between OncoGenex and Teva executed in 2009.. Under the initial agreement reached by OncoGenex and Teva, OncoGenex will receive a $27 million payment from Teva following execution of the final agreement to terminate the collaboration between the...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415